Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

Same author

Comparative prognostic performance of the REBECCA score and the Tabernero classification in refractory metastatic colorectal cancer treated with regorafenib: a multicenter real-world study.

BMC cancer·2026

Same author

Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study.

Clinical genitourinary cancer·2025

Same author

Correction: Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2025

Same author

Clinical advances and practice updates in genitourinary cancers: a 2024 review from the multidisciplinary Spanish 'Cambados annual meeting'.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2025

Same author

Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2024

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Renal cell carcinoma: complete response.

Ovidio Fernández Calvo¹, Diana Dopico Vázquez, Margarita Reboredo López

¹Medical Oncology Service, University Hospital Complex, A Coruña, Spain. ovidiofernandezcalvo@yahoo.es

Anti-Cancer Drugs

|January 30, 2010

Summary

This summary is machine-generated.

Sunitinib effectively treated metastatic clear cell renal cell carcinoma in a patient with recurrent disease after initial surgery. Re-initiation of sunitinib achieved a complete response, demonstrating its efficacy in managing advanced kidney cancer.

Related Experiment Videos

Last Updated: Jun 16, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Area of Science:

Oncology
Nephrology
Pharmacology

Background:

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer.
Metastatic ccRCC often requires systemic therapy after initial treatment failure.

Observation:

A 63-year-old male with stage II ccRCC underwent nephrectomy, later developing lung metastases.
Initial treatment with sunitinib showed good tolerance and disease control, followed by treatment interruption.
Disease progression occurred after treatment cessation, prompting re-initiation of sunitinib.

Findings:

Sunitinib treatment resulted in no evidence of disease recurrence for over a year.
Re-initiation of sunitinib following disease progression led to a complete response.
The patient tolerated sunitinib well, with manageable side effects (erythrodisesthesia, thrombocytopenia).

Implications:

Sunitinib demonstrates efficacy in managing recurrent and metastatic clear cell renal cell carcinoma.
Intermittent therapy and re-challenge with sunitinib may be viable strategies for advanced ccRCC.
This case highlights the potential for long-term disease control in metastatic ccRCC with targeted therapy.